Trabectedin

Sandra D’Angelo, MD, discussed a clinical trial on trabectedin in combination with low-dose irinotecan in Ewing sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to topline data released by the agent’s manufacturer.

Intermittent milademetan appeared effective and mitigated dose-limiting hematologic adverse events among patients with advanced solid tumors and lymphomas, according to study results published in Journal of Clinical Oncology.